Mifepristone modulates glucosylceramide synthase expression and reverse multidrug resistance in ovarian cancer cells.
- Author:
Ying LIU
1
;
Li-li WANG
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; pharmacology; Cell Line, Tumor; Cisplatin; pharmacology; Dose-Response Relationship, Drug; Drug Resistance, Multiple; drug effects; Drug Resistance, Neoplasm; drug effects; Female; Gene Expression Regulation, Enzymologic; drug effects; Gene Expression Regulation, Neoplastic; drug effects; Glucosyltransferases; genetics; Hormone Antagonists; pharmacology; Humans; Mifepristone; pharmacology; Ovarian Neoplasms; enzymology; genetics; pathology; RNA, Messenger; genetics; metabolism; Reverse Transcriptase Polymerase Chain Reaction
- From: Journal of Southern Medical University 2008;28(9):1727-1730
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the effect of mifepristone in reversing multidrug resistance(MDR) and modulating glucosylceramide synthase (GCS) mRNA expression in human ovarian cancer COC(1)/DDP cells.
METHODSMDR cell line COC(1)/DDP was treated with mifepristone at different concentrations. The alterations in the chemosensitivity of the cells to cisplatin (DDP) were evaluated by MTT assay. GCS mRNA expression in COC(1)/DDP cells were detected using RT-PCR before and after mifepristone treatment.
RESULTSThe expression level of GCS mRNA was 1.1792 in COC(1)/DDP cells, significantly higher than that in COC(1) cells (0.2836). Mifepristone at 1.25-10 micromol/L increased the sensitivity of COC(1)/DDP cells to cisplatin, and inhibited GCS expression at the mRNA level, showing concentration-dependent modulation of MDR and gene expression in the cells.
CONCLUSIONMifepristone can dose-dependently lower cisplatin resistance of COC(1)/DDP cells, the mechanism of which involves inhibition of GCS expression.
